Merck

In Zetia antitrust case, Merck and Glenmark ink deals with 2 plaintiff groups as retailers hold out
In Zetia antitrust case, Merck and Glenmark ink deals with 2 plaintiff groups as retailers hold out
Fierce Pharma
Merck
Glenmark
Zetia
pay-for-delay
antitrust
legal
Flag link:
Moderna and Merck’s mRNA Cancer Vaccine Impresses but Experts Urge Caution
Moderna and Merck’s mRNA Cancer Vaccine Impresses but Experts Urge Caution
BioSpace
Moderna Therapeutics
Merck
MRNA
cancer vaccines
vaccines
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma’s biggest spenders revealed: 2022 edition
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
M&A
R&D
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Novartis
Pfizer
Roche
Sanofi
Flag link:
Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A
Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A
Fierce Pharma
Big Pharma
M&A
Merck
Prometheus Biosciences
GSK
Bellus Health
Flag link:
In Pfizer's $43B acquisition of Seagen, the biotech's patience paid off
In Pfizer's $43B acquisition of Seagen, the biotech's patience paid off
Fierce Pharma
Pfizer
Seagen
M&A
Merck
Flag link:
Merck’s latest deal turns up the spotlight on immune system drugmakers
Merck’s latest deal turns up the spotlight on immune system drugmakers
BioPharma Dive
Merck
M&A
Prometheus Biosciences
immunology
Flag link:
Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda
Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda
Biopharma Reporter
Merck
Moderna Therapeutics
cancer
cancer vaccines
Keytruda
clinical trials
Flag link:
Merck to buy inflammatory disease drugmaker Prometheus for $10.8B
Merck to buy inflammatory disease drugmaker Prometheus for $10.8B
BioPharma Dive
Merck
M&A
Prometheus Biosciences
IBD
Flag link:
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Fierce Biotech
Junshi Biosciences
PARP inhibitors
ovarian cancer
Merck
AstraZeneca
Lynparza
Flag link:
Court Orders Merck to Produce Entire Database of Gardasil Adverse Events
Court Orders Merck to Produce Entire Database of Gardasil Adverse Events
EIN Newswires
legal
Merck
vaccines
Gardasil
Flag link:
Moderna Stock Yo-Yoes Winning A Key Battle For Its Cancer Vaccine
Moderna Stock Yo-Yoes Winning A Key Battle For Its Cancer Vaccine
Investors Business Daily
Moderna Therapeutics
Merck
MRNA
cancer
vaccines
Europe
cancer vaccine
Flag link:
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
BioSpace
Merck
Keytruda
Eisai
Lenvima
melanoma
clinical trials
cancer
colorectal cancer
Flag link:
Proxygen, averaging a new collab every 10 months, sticks $2.5B molecular glue deal with Merck
Proxygen, averaging a new collab every 10 months, sticks $2.5B molecular glue deal with Merck
Fierce Biotech
Merck
Proxygen
molecular glue
protein degradation
Flag link:
FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer
FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer
BioSpace
Merck
Seagen
Astellas
Keytruda
Padcev
metastatic urothelial carcinoma
FDA
Flag link:
Go or no go? Seagen's Padcev eyes FDA approval
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Flag link:
FDA grants full approval to Keytruda in tumor-agnostic setting
FDA grants full approval to Keytruda in tumor-agnostic setting
Endpoints
Merck
Keytruda
tumor agnostic
solid tumors
Flag link:
Top 10 pharma R&D budgets in 2022
Top 10 pharma R&D budgets in 2022
Fierce Biotech
R&D
Roche
JNJ
Merck
Pfizer
Novartis
AstraZeneca
Bristol Myers Squibb
Eli Lilly
Sanofi
AbbVie
Flag link:
In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda
In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda
Fierce Pharma
GSK
Merck
Keytruda
Jemperli
cancer
Flag link:
AACR 2023 – Moderna's immunotherapeutic splash
AACR 2023 – Moderna's immunotherapeutic splash
EP Vantage
AACR
Moderna Therapeutics
Allogene
AstraZeneca
Merck
Roche
Novartis
Eli Lilly
Innovent
Springworks
Biogene
Relay Therapeutics
Vivace Therapeutics
Flag link:

Pages